Literature DB >> 29531900

Nivolumab as first-line treatment in non-small cell lung cancer patients-key factors: tumor mutation burden and PD-L1 ≥50.

Paul Zarogoulidis1, Vasilis Papadopoulos2, Elena Maragouli2, George Papatsibas2, Chrysanthi Sardeli3, Yan-Gao Man4, Chong Bai5, Haidong Huang5.   

Abstract

Entities:  

Year:  2018        PMID： 29531900      PMCID： PMC5835639          DOI： 10.21037/tlcr.2018.01.04

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  19 in total

Review 1.  Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review.

Authors:  Shinkichi Takamori; Gouji Toyokawa; Kazuki Takada; Fumihiro Shoji; Tatsuro Okamoto; Yoshihiko Maehara
Journal:  Clin Lung Cancer       Date:  2017-07-06       Impact factor: 4.785

2.  Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.

Authors:  M Ilie; E Long-Mira; C Bence; C Butori; S Lassalle; L Bouhlel; L Fazzalari; K Zahaf; S Lalvée; K Washetine; J Mouroux; N Vénissac; M Poudenx; J Otto; J C Sabourin; C H Marquette; V Hofman; P Hofman
Journal:  Ann Oncol       Date:  2015-10-19       Impact factor: 32.976

3.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

Review 4.  Radiation Therapy Plus Anti-Programmed Death Ligand 1 Immunotherapy: A Review on Overall Survival.

Authors:  Elizabeth Marie Krcik
Journal:  Radiol Technol       Date:  2016-09

5.  PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.

Authors:  Jonas J Heymann; William A Bulman; David Swinarski; Carlos A Pagan; John P Crapanzano; Mehrvash Haghighi; Ladan Fazlollahi; Mark B Stoopler; Joshua R Sonett; Adrian G Sacher; Catherine A Shu; Naiyer A Rizvi; Anjali Saqi
Journal:  Cancer Cytopathol       Date:  2017-10-12       Impact factor: 5.284

6.  Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analyses.

Authors:  F Oezkan; Am Khan; P Zarogoulidis; W Hohenforst-Schmidt; D Theegarten; K Yasufuku; T Nakajima; L Freitag; K Darwiche
Journal:  Onco Targets Ther       Date:  2014-11-10       Impact factor: 4.147

7.  The novel 19G endobronchial USS (EBUS) needle samples processed as tissue "core biopsies" facilitate PD-L1 and other biomarker testing in lung cancer specimens: case report and the view point from the Respiratory Physician and the Pathologist.

Authors:  Samantha Herath; Wendy A Cooper
Journal:  Respirol Case Rep       Date:  2017-09-10

8.  Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment.

Authors:  Paul Zarogoulidis; Evaggelia Athanasiou; Theodora Tsiouda; Dimitrios Hatzibougias; Haidong Huang; Chong Bai; Georgia Trakada; Lemonia Veletza; Anastasios Kallianos; Christoforos Kosmidis; Nikolaos Barbetakis; Dimitrios Paliouras; Aggeliki Rapti; Dimitrios Drougas; Wolfgang Hohenforst-Schmidt
Journal:  Respir Med Case Rep       Date:  2017-08-29

9.  Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome.

Authors:  Wafa Amer; Csaba Toth; Erik Vassella; Jeannine Meinrath; Ulrike Koitzsch; Anne Arens; Jia Huang; Hannah Eischeid; Alexander Adam; Reinhard Buettner; Andreas Scheel; Stephan C Schaefer; Margarete Odenthal
Journal:  Sci Rep       Date:  2017-09-11       Impact factor: 4.379

10.  Multiple guided technologies based on radial probe endobronchial ultrasound for the diagnosis of solitary peripheral pulmonary lesions: a single-center study.

Authors:  Huang Haidong; Ning Yunye; Zhang Wei; Paul Zarogoulidis; Wolfgang Hohenforst-Schmidt; Yan-Gao Man; Yang Yuguang; Dong Yuchao; Bai Chong
Journal:  J Cancer       Date:  2017-09-29       Impact factor: 4.207
View more
  5 in total

Review 1.  Antitumour dendritic cell vaccination in a priming and boosting approach.

Authors:  Alexandre Harari; Michele Graciotti; Michal Bassani-Sternberg; Lana E Kandalaft
Journal:  Nat Rev Drug Discov       Date:  2020-08-06       Impact factor: 84.694

Review 2.  [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].

Authors:  Di Zhang; Jiaqi Huang; Chufeng Zhang; Yan Guan; Qisen Guo
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-06-20

3.  Tumor mutation burden derived from small next generation sequencing targeted gene panel as an initial screening method.

Authors:  Yuan Tang; Yuli Li; Weiya Wang; Analyn Lizaso; Ting Hou; Lili Jiang; Meijuan Huang
Journal:  Transl Lung Cancer Res       Date:  2020-02

4.  Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.

Authors:  Brendan P Hodkinson; Michael Schaffer; Joshua D Brody; Wojciech Jurczak; Cecilia Carpio; Dina Ben-Yehuda; Irit Avivi; Ann Forslund; Muhit Özcan; John Alvarez; Rob Ceulemans; Nele Fourneau; Anas Younes; Sriram Balasubramanian
Journal:  Transl Oncol       Date:  2020-12-06       Impact factor: 4.243

5.  Cryobiopsy for pneumonitis diagnosis in NSCLC immunotherapy.

Authors:  Paul Zarogoulidis; Christoforos Kosmidis; Eleni-Isidora Perdikouri; Wolfgang Hohemforst-Schmidt; Chrisanthi Sardeli
Journal:  Respir Med Case Rep       Date:  2022-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.